SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-029564
Filing Date
2024-06-24
Accepted
2024-06-24 16:03:36
Documents
17
Period of Report
2024-06-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20240624.htm   iXBRL 8-K 34865
2 EX-10.1 ex-101varkiemploymentagree.htm EX-10.1 91691
3 EX-10.2 ex-102varkiamendedemployme.htm EX-10.2 10528
4 EX-99.1 ex-991cloappointment.htm EX-99.1 13341
8 GRAPHIC avalologo.jpg GRAPHIC 8535
  Complete submission text file 0001628280-24-029564.txt   311927

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20240624.xsd EX-101.SCH 1969
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20240624_lab.xml EX-101.LAB 21026
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20240624_pre.xml EX-101.PRE 12041
20 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20240624_htm.xml XML 2625
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 241064225
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)